{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T15:16:32Z","timestamp":1784128592058,"version":"3.55.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,31]],"date-time":"2024-10-31T00:00:00Z","timestamp":1730332800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GSK plc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.clml.2024.10.001","type":"journal-article","created":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T10:17:54Z","timestamp":1729073874000},"page":"199-211","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Longitudinal Assessment of Transfusion Intensity in Patients With JAK Inhibitor\u2013Naive or \u2013Experienced Myelofibrosis Treated With Momelotinib"],"prefix":"10.1016","volume":"25","author":[{"given":"Claire N.","family":"Harrison","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruben","family":"Mesa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3361-3981","authenticated-orcid":false,"given":"Moshe","family":"Talpaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikas","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron T.","family":"Gerds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Perkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeow Tee","family":"Goh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Laura","family":"Fox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donal","family":"McLornan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanne","family":"Palmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynda","family":"Foltz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Vannucchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1011-8171","authenticated-orcid":false,"given":"Steffen","family":"Koschmieder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Passamonti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung-Eun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Ellis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan","family":"Strouse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco J.","family":"Gonzalez Carreras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen T.","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.clml.2024.10.001_bib0001","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1002\/ajh.26050","article-title":"Primary myelofibrosis: 2021 update on diagnosis, risk-stratification and management","volume":"96","author":"Tefferi","year":"2021","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.clml.2024.10.001_bib0002","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1097\/HS9.0000000000000001","article-title":"Myelofibrosis-related anemia: current and emerging therapeutic strategies","volume":"1","author":"Naymagon","year":"2017","journal-title":"Hemasphere"},{"issue":"13","key":"10.1016\/j.clml.2024.10.001_bib0003","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1182\/blood-2008-07-170449","article-title":"New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment","volume":"113","author":"Cervantes","year":"2009","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.clml.2024.10.001_bib0004","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1002\/cncr.34722","article-title":"Ruxolitinib in cytopenic myelofibrosis: response, toxicity, drug discontinuation, and outcome","volume":"129","author":"Palandri","year":"2023","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.clml.2024.10.001_bib0005","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.clinthera.2014.02.016","article-title":"Use of the functional assessment of cancer therapy \u2212 anemia in persons with myeloproliferative neoplasm-associated myelofibrosis and anemia","volume":"36","author":"Tefferi","year":"2014","journal-title":"Clin Ther"},{"issue":"1","key":"10.1016\/j.clml.2024.10.001_bib0006","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3324\/haematol.2010.031831","article-title":"Red blood cell transfusion-dependency implies a poor survival in primary myelofibrosis irrespective of IPSS and DIPSS","volume":"96","author":"Elena","year":"2011","journal-title":"Haematologica"},{"issue":"suppl 16","key":"10.1016\/j.clml.2024.10.001_bib0007","doi-asserted-by":"crossref","first-page":"7066","DOI":"10.1200\/JCO.2023.41.16_suppl.7066","article-title":"Impact of transfusion burden on health-related quality of life (HRQOL) and functioning in patients (pts) with myelofibrosis (MF): post hoc analysis of SIMPLIFY-1 (S1) and -2 (S2)","volume":"41","author":"Mesa","year":"2023","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.clml.2024.10.001_bib0008","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1182\/bloodadvances.2021006889","article-title":"A prognostic model to predict survival after 6 months of ruxolitinib in patients with myelofibrosis","volume":"6","author":"Maffioli","year":"2022","journal-title":"Blood Adv"},{"issue":"suppl 1","key":"10.1016\/j.clml.2024.10.001_bib0009","doi-asserted-by":"crossref","first-page":"3974","DOI":"10.1182\/blood-2022-162657","article-title":"The burden of illness and the incremental burden of transfusion dependence in myelofibrosis in the United States","volume":"140","author":"Gerds","year":"2022","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2024.10.001_bib0010","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13045-021-01157-4","article-title":"Momelotinib: an emerging treatment for myelofibrosis patients with anemia","volume":"15","author":"Chifotides","year":"2022","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.clml.2024.10.001_bib0011","unstructured":"GSK. Ojjaara. Prescribing information. GSK; 2023. Accessed: August 13, 2024. Available at: https:\/\/gskpro.com\/content\/dam\/global\/hcpportal\/en_US\/Prescribing_Information\/Ojjaara\/pdf\/OJJAARA-PI-PIL.PDF."},{"key":"10.1016\/j.clml.2024.10.001_bib0012","unstructured":"GSK. Omjjara. Summary of product characteristics. GlaxoSmithKline Trading Services Limited. Accessed: August 13, 2024. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/omjjara-epar-product-information_en.pdf."},{"issue":"18","key":"10.1016\/j.clml.2024.10.001_bib0013","doi-asserted-by":"crossref","first-page":"4282","DOI":"10.1182\/bloodadvances.2020002662","article-title":"ACVR1\/JAK1\/JAK2 inhibitor momelotinib reverses transfusion dependency and suppresses hepcidin in myelofibrosis phase 2 trial","volume":"4","author":"Oh","year":"2020","journal-title":"Blood Adv"},{"issue":"10373","key":"10.1016\/j.clml.2024.10.001_bib0014","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S0140-6736(22)02036-0","article-title":"Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study","volume":"401","author":"Verstovsek","year":"2023","journal-title":"Lancet"},{"issue":"34","key":"10.1016\/j.clml.2024.10.001_bib0015","doi-asserted-by":"crossref","first-page":"3844","DOI":"10.1200\/JCO.2017.73.4418","article-title":"SIMPLIFY-1: a phase III randomized trial of momelotinib versus ruxolitinib in Janus kinase inhibitor-naive patients with myelofibrosis","volume":"35","author":"Mesa","year":"2017","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.clml.2024.10.001_bib0016","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1016\/S2352-3026(17)30237-5","article-title":"Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial","volume":"5","author":"Harrison","year":"2018","journal-title":"Lancet Haematol"},{"issue":"11","key":"10.1016\/j.clml.2024.10.001_bib0017","doi-asserted-by":"crossref","first-page":"703","DOI":"10.2217\/fon-2023-0964","article-title":"Anemia-related response end points in myelofibrosis clinical trials: current trends and need for renewed consensus","volume":"20","author":"Klencke","year":"2024","journal-title":"Future Oncol"},{"issue":"14","key":"10.1016\/j.clml.2024.10.001_bib0018","doi-asserted-by":"crossref","first-page":"3582","DOI":"10.1182\/bloodadvances.2022009311","article-title":"Momelotinib long-term safety and survival in myelofibrosis: integrated analysis of phase 3 randomized controlled trials","volume":"7","author":"Verstovsek","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2024.10.001_bib0019","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2147\/OTT.S53348","article-title":"Management of cytopenias in patients with myelofibrosis treated with ruxolitinib and effect of dose modifications on efficacy outcomes","volume":"7","author":"Verstovsek","year":"2013","journal-title":"Onco Targets Ther"},{"issue":"6","key":"10.1016\/j.clml.2024.10.001_bib0020","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1007\/s00277-020-04002-9","article-title":"Management of myelofibrosis after ruxolitinib failure","volume":"99","author":"Harrison","year":"2020","journal-title":"Ann Hematol"},{"issue":"suppl 1","key":"10.1016\/j.clml.2024.10.001_bib0021","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.1182\/blood-2023-178816","article-title":"Clinical effectiveness and safety of momelotinib compared with continued ruxolitinib or best available therapy in patients with myelofibrosis who required red blood cell transfusions: subgroup analysis of the phase 3 SIMPLIFY-2 study","volume":"142","author":"Harrison","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.clml.2024.10.001_bib0022","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1080\/10428194.2024.2328800","article-title":"Momelotinib vs. ruxolitinib in myelofibrosis patient subgroups by baseline hemoglobin levels in the SIMPLIFY-1 trial","volume":"65","author":"Gupta","year":"2024","journal-title":"Leuk Lymphoma"},{"issue":"suppl","key":"10.1016\/j.clml.2024.10.001_bib0023","doi-asserted-by":"crossref","first-page":"e85817f0","DOI":"10.1097\/01.HS9.0000975492.85817.f0","article-title":"PB2185: Effect of new or worsening anemia on clinical outcomes in patients with myelofibrosis (MF) treated with ruxolitinib (RUX): a post hoc analysis of the COMFORT-I and -II trials","volume":"8","author":"Al-Ali","year":"2023","journal-title":"Hemasphere"},{"issue":"12","key":"10.1016\/j.clml.2024.10.001_bib0024","doi-asserted-by":"crossref","first-page":"e482","DOI":"10.3324\/haematol.2016.151449","article-title":"The impact of anemia on overall survival in patients with myelofibrosis treated with ruxolitinib in the COMFORT studies","volume":"101","author":"Gupta","year":"2016","journal-title":"Haematologica"},{"issue":"suppl 1","key":"10.1016\/j.clml.2024.10.001_bib0025","doi-asserted-by":"crossref","first-page":"5174","DOI":"10.1182\/blood-2023-179417","article-title":"Effect of new or worsening anemia on clinical outcomes in 2233 patients with myelofibrosis treated with ruxolitinib in the expanded-access JUMP study","volume":"142","author":"Gupta","year":"2023","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.clml.2024.10.001_bib0026","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1080\/10428194.2022.2043304","article-title":"Momelotinib reduces transfusion requirements in patients with myelofibrosis","volume":"63","author":"Mesa","year":"2022","journal-title":"Leuk Lymphoma"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265024023590?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265024023590?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T12:47:18Z","timestamp":1739364438000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265024023590"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S2152265024023590"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2024.10.001","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Longitudinal Assessment of Transfusion Intensity in Patients With JAK Inhibitor\u2013Naive or \u2013Experienced Myelofibrosis Treated With Momelotinib","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2024.10.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}